Related Experiment Video
Updated: Jan 7, 2026
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
Blockade of experimental atopic dermatitis via topical NF-kappaB decoy oligonucleotide
Maya Dajee1, Tony Muchamuel, Brian Schryver
1Department of Research, Corgentech. Inc., South San Francisco, California, USA.
Abstract:
Atopic dermatitis (AD) is a common chronic skin inflammatory disease. Long-term use of topical corticosteroids in skin inflammation poses risks of systemic and local side effects. The NF-kappaB transcription factor family plays a central role in the progression and maintenance of AD. This study explores the possibility of using topical NF-kappaB Decoy as a novel therapeutic alternative for targeting Th1/Th2-driven skin inflammation in experimental AD. A high-affinity, topical NF-kappaB Decoy developed for human efficacy demonstrates: (i) efficient NF-kappaB Decoy penetration in pig skin, (ii) NF-kappaB Decoy nuclear localization in keratinocytes and key immune cells, and (iii) potent "steroid-like" efficacy in a chronic dust-mite antigen skin inflammation treatment model. NF-kappaB Decoy exerts its anti-inflammatory action through the effective inhibition of essential regulators of inflammation and by induction of apoptosis of key immune cells. Unlike betamethasone valerate (BMV), long-term NF-kappaB Decoy treatment does not induce skin atrophy. Moreover, topical NF-kappaB Decoy, in contrast to BMV, restores compromised stratum corneum integrity and barrier function. Steroid withdrawal causes rapid rebound of inflammation, while the NF-kappaB Decoy therapeutic benefit was maintained for weeks. Thus, topical NF-kappaB Decoy provides a novel mechanism of reducing chronic skin inflammation with improved skin homeostasis and minimal side effects.
Insights
Topical NF-kappaB Decoy offers a novel therapy for atopic dermatitis (AD), reducing skin inflammation without side effects like skin atrophy. This treatment maintains benefits after withdrawal, unlike corticosteroids.
Area of Science:
- Dermatology
- Immunology
- Molecular Biology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- Topical corticosteroids, while effective, carry risks of local and systemic side effects with long-term use.
- The NF-kappaB transcription factor is crucial in AD pathogenesis.
Purpose of the Study:
- To investigate topical NF-kappaB Decoy as a novel therapeutic for Th1/Th2-driven skin inflammation in experimental AD.
- To evaluate the efficacy and safety of NF-kappaB Decoy compared to corticosteroids.
Main Methods:
- Development of a high-affinity topical NF-kappaB Decoy for human efficacy.
- Assessment of NF-kappaB Decoy penetration and localization in pig skin and immune cells.
- Evaluation of efficacy in a chronic dust-mite antigen-induced skin inflammation model in comparison to betamethasone valerate (BMV).
Main Results:
- NF-kappaB Decoy demonstrated efficient skin penetration and nuclear localization in relevant cells.
- It exhibited potent anti-inflammatory effects, inhibiting inflammation regulators and inducing immune cell apoptosis.
- Unlike BMV, NF-kappaB Decoy did not cause skin atrophy and restored skin barrier function.
- Therapeutic benefits were sustained post-treatment, without the rebound inflammation seen with steroid withdrawal.
Conclusions:
- Topical NF-kappaB Decoy is a promising therapeutic alternative for AD, offering sustained anti-inflammatory action.
- It provides a novel mechanism with improved skin homeostasis and a favorable safety profile compared to corticosteroids.
